Prostate Cancer Diagnosis
Prostate Cancer Diagnosis
The diagnostic pathway for prostate cancer runs in a fixed order: a PSA test and examination raise the question, multiparametric MRI localises the suspicious area, MRI-targeted biopsy answers it, and the pathologist's grade group together with imaging determines the risk category. Each step exists to make the next one more precise.
The PSA test and what it does not tell you
Prostate-specific antigen is a protein produced by prostate cells — normal cells as well as cancer cells — and measured in blood. That single fact explains both its value and its limits: it is organ-specific but not cancer-specific. It rises with benign enlargement, with inflammation and infection, after ejaculation, after a rectal examination and after cycling, as well as with cancer.
What the test is good at is signalling that something in the prostate has changed. What it cannot do is tell you what that something is, or even how serious it is: a man with a PSA of 6 may have benign enlargement, and a man with a PSA of 4 may have a significant tumour. This is why the number alone never justifies treatment, and why the pathway moves on to imaging and biopsy rather than to a decision.
Two practical details matter to accuracy. A PSA should not be measured within a couple of days of ejaculation, vigorous cycling or a urinary infection, and it should be repeated before anything is concluded from a single raised value. Equally important is the trend: the rate at which PSA rises across successive tests carries information a single measurement does not, which is why bringing a history of results is more useful than bringing the most recent one.
Multiparametric MRI and PI-RADS
Multiparametric MRI is the step that changed prostate diagnosis. It combines anatomical imaging with functional sequences to show not only the size of the gland but where within it a suspicious lesion lies, and how likely that lesion is to be significant cancer. The radiologist reports it with a PI-RADS score from 1 to 5, where higher numbers indicate a greater likelihood of clinically significant disease.
The score has two uses. It guides the biopsy — a PI-RADS 4 or 5 lesion is sampled directly, which is what makes targeted biopsy more accurate than the blind systematic sampling that preceded it. And a low score with a modest PSA supports a decision to keep monitoring rather than to biopsy immediately, which spares a proportion of men an unnecessary procedure.
One limitation is worth stating plainly: MRI is good at significant tumours and less reliable for small, low-grade ones. A normal-looking MRI therefore does not exclude low-grade cancer, and where the PSA trend or the examination is strongly suspicious, biopsy may still be performed despite a low PI-RADS score. The scan improves the odds of finding what matters; it does not replace the tissue diagnosis.
The biopsy
The biopsy makes the diagnosis, and how it is performed affects both accuracy and safety. Two questions define the procedure:
- Where are the needles aimed? — MRI-targeted sampling of the lesion identified on the scan, combined with systematic sampling of the rest of the gland so that disease outside the visible lesion is not missed.
- By which route? — the transperineal route, passing the needles through the skin between the scrotum and anus, has largely replaced the transrectal route in current practice because it carries a substantially lower risk of infection and does not require bowel preparation.
The procedure is usually done under local or light general anaesthesia, takes around twenty minutes, and is followed by blood in the semen and sometimes in the urine for a week or two. The important output is not a yes-or-no answer alone but a set of numbers: how many cores contained cancer, what proportion of each core was involved, and the grade pattern — all of which feed the risk category.
Grade group: the number that matters most
Grading is where prostate cancer reporting changed most. A pathologist grades the two most common architectural patterns in the specimen from 3 to 5, adds them to produce the familiar Gleason sum, and then the sum is converted into a grade group from 1 to 5, where group 1 is the least aggressive and group 5 the most. The conversion exists because the older sum hid important differences:
- Group 1 (Gleason 3+3=6) — the least aggressive pattern; often suitable for active surveillance.
- Group 2 (3+4=7) — mostly pattern 3 with a minority of pattern 4; the proportion of pattern 4 matters.
- Group 3 (4+3=7) — pattern 4 predominates, and behaviour is more aggressive than group 2 despite the same Gleason sum.
- Group 4 (8) — high grade, usually treated as high-risk disease.
- Group 5 (9–10) — the most aggressive pattern, with the highest likelihood of spread.
The practical request for any patient is straightforward: ask for the grade group, not just the Gleason sum, and ask for the percentage of pattern 4 if the report includes it — those numbers drive the risk category, and the risk category drives the treatment route. Some reports also note intraductal or cribriform patterns, which raise concern even when the grade group looks modest, and those findings belong in the discussion as well.
Staging with PSMA PET-CT
Once the diagnosis and grade are established, staging answers whether the disease is confined to the prostate — and in higher-risk disease, PSMA PET-CT has become the most informative single test. A tracer that binds prostate-specific membrane antigen shows up on a scan wherever prostate cancer cells are, including deposits in lymph nodes and bone that conventional bone scan and CT can miss, particularly at low PSA levels.
Its consequences are specific. PSMA imaging can move a man with high-risk localised disease into the node-positive or metastatic category — which changes the treatment from local therapy alone to a systemic-plus-local plan. It identifies the site of recurrence when PSA rises after previous treatment, at levels far below what older scans can localise, and that localisation is what makes targeted salvage treatment possible. And high tracer uptake is what qualifies a patient for PSMA radioligand therapy in advanced disease.
For lower-risk disease, staging imaging is often unnecessary, because the probability of spread is low and the finding would not change the plan. The general rule is that the intensity of staging should match the risk category — which is one reason the grade group and PSA value should be known before a scan is ordered.
What we do with your records
The assessment quality depends on whether the file records the right things, and prostate cancer is unusual in needing a series of PSA values rather than one. The items that let our team give a complete answer:
- The PSA history with dates, not just the latest result
- The biopsy pathology report, including the grade group, the number of cores involved and the percentage of pattern 4
- The multiparametric MRI report with the PI-RADS score, and the images if available
- Any PSMA PET-CT, bone scan or CT already performed
- Any germline genetic result, or the family history that would justify testing
- A short medication list and recent blood results, including renal function
With those items, our urological oncology MDT returns a written assessment within 48 hours of the file being complete: the risk category the findings imply, the treatment routes that are open, whether surgery or radiotherapy suits the tumour's position within the gland, and what remains to be confirmed before travelling. Where the grade group is not stated in the report, or the MRI was reported without a PI-RADS score, we say so explicitly — those are the two gaps that most often hold up a decision.